for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

UPDATE 1-Bayer contraceptive probed over possible death link

* Young woman died mid-September of lung embolism

* Swissmedic says investigating (Adds Bayer stock price)

ZURICH, Sept 25 (Reuters) - Swiss medical authority Swissmedic said on Friday it was investigating suspicions of a possible link between the death of a woman from a blood clot 10 months after she was prescribed Bayer's BAYGn.DE low-dose oral contraceptive, Yaz.

The German drugmaker’s Swiss unit said in a statement that it was not able to comment on the case beyond saying it would take any possible link seriously. It expressed sympathy with the woman’s family, saying her death in mid-September was tragic regardless of whether there was a connection to its contraceptive pill.

Nine deaths in Switzerland since 1990 have been connected with oral contraceptives, according to Swissmedic. The authority said it began investigating all birth control pills after a 16-year-old was disabled by a lung embolism in May after taking Yaz.

Bayer launched Yaz last year in Europe, two years after it began selling it in the United States. The company said it expected the drug to generate peak annual European sales in the low triple-digit millions of euros within five years.

Yaz is the lower-dose version of Bayer’s contraceptive, Yasmin.

Bayer’s Yasmin, Yaz, and Yasminelle contraceptives were its best selling pharmaceutical products last year, generating sales of 1.2 billion euros last year.

Bayer’s stock rose 0.09 percent to 46.22 euros.

Reporting by Jason Rhodes; Editing by Richard Chang

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up